Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shield TherapeuticsFRA:1JS +8.22% 3-Year EPS without NRI Growth Rate is 50.10% as of Dec. 2025, which is 82% above its 10-year median of 27.50. The stock has 5 warning signs investors should review. Among 788 Drug Manufacturers companies, Shield Therapeutics ranks better than 87.31% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 50.10% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 17.80% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 13.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 12 years, the highest 3-Year average EPS without NRI Growth Rate of Shield Therapeutics was 50.10% per year. The lowest was -74.50% per year. And the median was 27.50% per year.
Shield Therapeutics (FRA:1JS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Shield Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
FRA:1JS vs ZTS, UTHR, VTRS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Shield Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 50.10% mean?
Shield Therapeutics (FRA:1JS) has a 3-Year EPS without NRI Growth Rate of 50.10% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Shield Therapeutics and its competitors. This is 82% above median its historical median of 27.50. According to the industry distribution chart, Shield Therapeutics ranks #100 out of 788 companies in the Drug Manufacturers industry, placing it in the top 12.7%.
Is Shield Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Shield Therapeutics' current 3-Year EPS without NRI Growth Rate of 50.10% is 82% above median its 10-year median of 27.50. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.65. Shield Therapeutics' value of 50.10% is 419.2% above this industry median. Based on the distribution chart, Shield Therapeutics ranks #100 out of 788 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Shield Therapeutics' 3-Year EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #100 out of 788 companies for 3-Year EPS without NRI Growth Rate. This places Shield Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.65. Shield Therapeutics' value of 50.10% is 419.2% above this benchmark. While the company's 10-year median is 27.50 vs. the industry median of 9.65, Shield Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.65, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shield Therapeutics's current 3-Year EPS without NRI Growth Rate of 50.10% is 419.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current 3-Year EPS without NRI Growth Rate is 50.10%, which is 82% above median its own 10-year median of 27.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (FRA:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.09, compared to a current price of €0.04 — trading 56.1% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 50.10%, which is 82% above median its 10-year median of 27.50 and 419.2% above the Drug Manufacturers industry median of 9.65. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Shield Therapeutics (FRA:1JS), the current 3-Year EPS without NRI Growth Rate is 50.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1JS has been successfully added to your 
